aTyr Pharma price target raised to $20 from $13 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on aTyr Pharma to $20 from $13 and keeps an Overweight rating on the shares. The analyst views the company’s efzofitimod as a “diamond in the rough in the pulmonary world.” Efzofitimod has a blockbuster opportunity to be potentially positioned as the first-line standard of care drug in sarcoidosis, the analyst tells investors in a research note. The firm says aTyr shares are overlooked and undervalued.